Pfizer Inc. and BioNTech SE announced on Wednesday, May 6, 2020, that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enrol up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with ...
Taiwan says request to drop word ‘country’ preceded BioNTech vaccine deal collapse
Germany’s BioNTech asked Taiwan to remove the word “country” from an announcement they planned to make on a COVID-19 vaccine sale to the island, its health minister said on Thursday, giving details of the deal whose axing was blamed on China by Taipei. Taiwan and China are engaged in an escalating war of words after Beijing offered the shots to the Chinese-claimed island via Shanghai Fosun Pharmaceutical Group Co Ltd, which has a contract to sell them in Greater China. Taiwan Health Minister Chen Shih-chung told a daily news briefing the government had signed and sent back a “final contract” agreed with BioNTech after months of negotiations, and the two sides were on the verge of issuing a press release on Jan. 8. But four hours later “BioNTech suddenly sent a letter, saying they strongly ...